CTOs on the Move

Ocularis Pharma

www.ocularispharma.com

 
Ocularis Pharma, Inc. is a Riverside, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Indicus Pharma

Indicus Pharma is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Team Wellness Center

Team Mental Health Services is dedicated to enhancing the well-being of individuals by providing an array of comprehensive behavioral and physical services in an environment that promotes quality of life, continuous improvement and social awareness. ...

Allarity Therapeutics

Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.

Capital i

BeClinic | Best WordPress theme for clinics and medicine

Sun Pharma

Sun Pharma is the world`s fourth largest specialty generic pharmaceutical company and India`s top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma`s global presence is supported by 50 manufacturing facilities spread across 5 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of over 7% of annual revenues.